Results 51 to 60 of about 2,619,226 (251)

Serial passaging in vitro generates a Vero cell-adapted coxsackievirus A6 strain with distinct phenotypic characteristics

Frontiers in Cellular and Infection Microbiology
BackgroundCoxsackievirus A6 (CVA6) has emerged as a major etiological agent of hand, foot, and mouth disease (HFMD), yet no commercial vaccine is available against CVA6.
Sijin Xia, Sijin Xia, Rongyu Shu, Rongyu Shu, Yihao Sun, Yihao Sun, Jiahui Wu, Jiahui Wu, Mengjun Wang, Mengjun Wang, Yaxin Du, Yaxin Du, Dongsheng Yang, Dongsheng Yang, Jing Guo, Jing Guo, Bo Zhang, Shuo Shen, Shuo Shen   +18 more
doaj   +1 more source

Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China

Emerging Microbes and Infections
Following the national dynamic zero-COVID strategy adjustment, the utilization of broad-spectrum nasal neutralizing antibodies may offer an alternative approach to controlling the outbreak of Omicron variants between late 2022 and early 2023 in China ...
Ying Liu, Jiayou Zhang, Wen Liu, Yongbing Pan, Shunan Ruan, Xuanxuan Nian, Wei Chen, Lina Sun, Qiangling Yin, Xin Yue, Qingliang Li, Fang Gui, Cong Wu, Shuzhen Wang, Yunkai Yang, Zhaofei Jing, Feiguang Long, Zejun Wang, Zeyu Zhang, Chaolin Huang, Kai Duan, Mifang Liang, Xiaoming Yang   +22 more
doaj   +1 more source

The Development of Rheumatoid Arthritis–Specific Ambulatory Care–Sensitive Conditions: Results of a Consensus Process

Arthritis Care &Research, EarlyView.
Objective Ambulatory care–sensitive conditions (ACSCs) serve as indicators of access, quality, and performance of the health system. This study aimed to determine rheumatoid arthritis (RA)‐specific ACSCs for use in the evaluation of care system access and quality.
Kara Irwin, Candace H. Feldman, Claire E. H. Barber, Gabriel Fabreau, Jake Jennings, Scott Patten, Cheryl Barnabe, Inflammatory Arthritis‐Specific ACSC Consensus Process Working Group   +7 more
wiley   +1 more source

Licensed and investigational TLR4 agonists as vaccine adjuvants: structural basis, clinical progress, and future directions

Frontiers in Immunology
The development of innovative vaccine platforms, including protein subunit and nucleic acid vaccines, has advanced rapidly and established new technical paradigms for infectious disease prophylaxis.
Jiasheng Zhou, Jiasheng Zhou, Jiasheng Zhou, Bo Liu, Bo Liu, Bo Liu, Qiao Yang, Qiao Yang, Qiao Yang, Jingxuan Zhou, Jingxuan Zhou, Jingxuan Zhou, Jiahao Zheng, Jiahao Zheng, Jiahao Zheng, Yujin Chen, Yujin Chen, Yujin Chen, Lie Fu, Lie Fu, Lie Fu, Jianhui Du, Jianhui Du, Jianhui Du, Zhegang Zhang, Zhegang Zhang, Zhegang Zhang, Jiayou Zhang, Jiayou Zhang, Jiayou Zhang, Changgui Li   +30 more
doaj   +1 more source

A Holistic Platform Approach for Developing Robust Pulmonary mRNA Delivery: Integrating Novel Phenolic Acid‐Derived Ionizable Lipids and Device Engineering

Advanced Functional Materials, EarlyView.
An integrated pulmonary mRNA delivery platform combining novel biodegradable syringic acid‐derived ionizable lipids, design‐of‐experiments formulation optimization, and vibrating‐mesh nebulizer engineering enabled stable aerosolization and efficient lung delivery.
Neha Kaushal, Younan Ma, Asad Khanmohammed, Dipen Parande, Hanming Zhang, Saket Dolare, Juliet Chen, Apiwat Wangweerawong, Saswata Karmakar, Hongfeng Deng, Frank Koppenhagen, Shraddha Sharma, Eric Reyes, Sherry He, Lianne Boeglin, Caroline Woo, Azadeh Paksa, Ayed Allawzi, Anusha Dias, Gregory Troiano, Shrirang Karve, Frank DeRosa   +21 more
wiley   +1 more source

Vaccine Interaction and Protection against Virulent Avian Metapneumovirus (aMPV) Challenge after Combined Administration of Newcastle Disease and aMPV Live Vaccines to Day-Old Turkeys

, 2023
Newcastle disease virus (NDV) and avian metapneumovirus (aMPV) are among the most impactful pathogens affecting the turkey industry. Since turkeys are routinely immunized against both diseases, the hatchery administration of the combined respective live ...
Mattia Cecchinato, Calogero Terregino, Giulia Graziosi, Elena Catelli, Matteo Legnardi, Valeria Listorti, Caterina Lupini   +6 more
core   +1 more source

Vaccines against toxoplasma gondii : challenges and opportunities [PDF]

, 2009
Development of vaccines against Toxoplasma gondii infection in humans is of high priority, given the high burden of disease in some areas of the world like South America, and the lack of effective drugs with few adverse effects.
Jongert, Erik, Förster-Wald, Elisabeth, Gargano, Nicola, Roberts, Craig W, Petersen, Eskild   +4 more
core   +4 more sources

Immune Imprinting Identified in Phage-Display Antibody Libraries Derived from Early Wild-Type and Late Omicron COVID-19 Convalescents

Viruses
The rapid evolution of SARS-CoV-2, particularly the emergence of Omicron subvariants, has significantly reduced the efficacy of existing vaccines and monoclonal antibodies.
Boyang Li, Mengxuan Wang, Fang Huang, Wei Wu, Jiaxin Fan, Lu Yang, Yongbing Pan, Mifang Liang, Kai Duan   +8 more
doaj   +1 more source

From Cell‐Derived Vesicles to Hybrid Nanovectors: Biological Membranes as Functional Blueprints for Gene Delivery

Advanced Healthcare Materials, EarlyView.
Biologically derived and hybrid nonviral nanovectors are examined as distinct but convergent design approaches. Integrating synthetic components with biologically functionalized membranes allows efficient interactions with complex cellular environments.
Clara Baldari, Claudia Leone, Gabriella Leccese, Claudia De Stradis, Alessandra Invidia, Concetta Quintarelli, Biagio De Angelis, Franco Locatelli, Giuseppe Gigli, Gabriele Maiorano, Ilaria Elena Palamà   +10 more
wiley   +1 more source

Improving cellular cancer vaccines [PDF]

, 2010
Immunization with cancer cells is of great demand in anti-cancer therapy. However, current cellular vaccines are inefficient and there are questions regarding their overall safety. We report a simple and straightforward approach for improving of cellular
Petr Lokhov
core